Literature DB >> 12075653

Ketamine dependence.

H R Pal1, N Berry, R Kumar, R Ray.   

Abstract

Ketamine hydrochloride is a safe and rapid-acting non-opioid, lipid soluble anaesthetic with a short elimination half-life that is used for medical and veterinary purposes. It produces a state of "dissociative anaesthesia", probably from action on N-methyl-D-aspartate (NMDA) receptors. The psychotropic effects of ketamine range from dissociation and depersonalization to psychotic experiences and include a sensation of feeling light, body distortion, absence of time sense, novel experiences of cosmic oneness and out-of-body experiences. Abuse of ketamine has been reported, the typical abuser being an individual who uses multiple drugs and has some contact with medical agencies. This case demonstrates the effects of large doses of ketamine in a person with polysubstance abuse. The case also highlights development of significant tolerance to ketamine without prominent withdrawal symptoms. Caution in use of ketamine is reiterated in light of its abuse liability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075653     DOI: 10.1177/0310057X0203000323

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  19 in total

1.  [Out-of-body experience as possible seizure symptom in a patient with a right parietal lesion].

Authors:  C Brandt; D Brechtelsbauer; C G Bien; K Reiners
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

3.  Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.

Authors:  Hyun-Sang Cho; Deepak C D'Souza; Ralitza Gueorguieva; Edward B Perry; Steven Madonick; Laurence P Karper; Anissa Abi-Dargham; Aysenil Belger; Walid Abi-Saab; Deborah Lipschitz; Alexandre Bennet; John P Seibyl; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

Review 4.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

5.  Severity of club drug dependence and perceived need for treatment among a sample of adult club drug users in Shanghai, China.

Authors:  Yingying Ding; Na He; Steven Shoptaw; Meiyang Gao; Roger Detels
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-29       Impact factor: 4.328

6.  Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats.

Authors:  Lawrence M Carey; Wan-Hung Lee; Tannia Gutierrez; Pushkar M Kulkarni; Ganesh A Thakur; Yvonne Y Lai; Andrea G Hohmann
Journal:  Neuroscience       Date:  2017-03-08       Impact factor: 3.590

Review 7.  Ketamine : from medicine to misuse.

Authors:  Kim Wolff; Adam R Winstock
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 8.  Club drugs: review of the 'rave' with a note of concern for the Indian scenario.

Authors:  Kaustav Chakraborty; Rajarshi Neogi; Debasish Basu
Journal:  Indian J Med Res       Date:  2011-06       Impact factor: 2.375

9.  Psychiatric side effects of medications prescribed in internal medicine.

Authors:  Rodrigo Casagrande Tango
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

10.  Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature.

Authors:  Sarah E Grady; Travis A Marsh; Allison Tenhouse; Kelsey Klein
Journal:  Ment Health Clin       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.